|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0022885,
umls-concept:C0035647,
umls-concept:C0039593,
umls-concept:C0040223,
umls-concept:C0205195,
umls-concept:C0205360,
umls-concept:C0241888,
umls-concept:C0449774,
umls-concept:C0458083,
umls-concept:C0525045,
umls-concept:C0681850,
umls-concept:C0871261,
umls-concept:C1550501,
umls-concept:C1704632,
umls-concept:C1706203,
umls-concept:C1706817,
umls-concept:C2349001,
umls-concept:C2697811,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-4-30
|
|
pubmed:abstractText |
One of the major neurobiological alterations in depressive disorders consists in a disturbed regulation of the hypothalamic-pituitary-adrenocortical (HPA) system. This is reflected by a pathological increase in the adrenocorticotropin (ACTH) and cortisol release after pretreatment with 1.5 mg dexamethasone (DEX) the previous night and a challenge with 100 micrograms corticotropin-releasing hormone (CRH) the next day. The changes evoked by this combined DEX-CRH test recede partially with an improvement of the psychopathological symptoms of depressed patients. It is still unclear, however, whether this long-lasting disturbance of the HPA system is due to acquired changes in the acute illness or whether it plays a causal role and could be considered as a trait or vulnerability marker for depression. In a previous study we have examined the HPA function of healthy probands with a high genetic load for affective disorders. We found that this group of high-risk probands (HRPs) showed abnormal DEX-CRH test results with a cortisol release that was between that of a control group and a group of patients with depression. In a follow-up study we now reexamined 14 of the 47 HRPs about 4 years after the index investigation and found surprisingly constant DEX-CRH test results, so that one of the requirements for a vulnerability marker is fulfilled.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0893-133X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
253-62
|
|
pubmed:dateRevised |
2011-5-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9509493-Adrenocorticotropic Hormone,
pubmed-meshheading:9509493-Adult,
pubmed-meshheading:9509493-Area Under Curve,
pubmed-meshheading:9509493-Corticotropin-Releasing Hormone,
pubmed-meshheading:9509493-Dexamethasone,
pubmed-meshheading:9509493-Female,
pubmed-meshheading:9509493-Follow-Up Studies,
pubmed-meshheading:9509493-Glucocorticoids,
pubmed-meshheading:9509493-Hormones,
pubmed-meshheading:9509493-Humans,
pubmed-meshheading:9509493-Hydrocortisone,
pubmed-meshheading:9509493-Male,
pubmed-meshheading:9509493-Middle Aged,
pubmed-meshheading:9509493-Mood Disorders,
pubmed-meshheading:9509493-Neurosecretory Systems,
pubmed-meshheading:9509493-Risk Factors
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders.
|
|
pubmed:affiliation |
Max Planck Institute of Psychiatry, Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
